Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial.
Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Weber MA, Black HR, Plouin PF, Levy D, Mancia G, Larochelle P, Kolloch RE, Alderman M, Ruilope LM, Dahlöf B, Flack JM, Wolf R; OPERA Study Group. Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events. Kostis JB, et al. Among authors: weber ma. Am J Hypertens. 2002 Feb;15(2 Pt 1):193-8. doi: 10.1016/s0895-7061(01)02048-9. Am J Hypertens. 2002. PMID: 11863257 Clinical Trial.
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA. Jamerson KA, et al. Among authors: weber ma. Am J Hypertens. 2004 Sep;17(9):793-801. doi: 10.1016/j.amjhyper.2004.05.004. Am J Hypertens. 2004. PMID: 15363822 Review.
Feasibility of treating prehypertension with an angiotensin-receptor blocker.
Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators. Julius S, et al. Among authors: weber ma. N Engl J Med. 2006 Apr 20;354(16):1685-97. doi: 10.1056/NEJMoa060838. Epub 2006 Mar 14. N Engl J Med. 2006. PMID: 16537662 Free article. Clinical Trial.
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimský J, Zanchetti A; VALUE Trial Investigators. Kjeldsen SE, et al. Among authors: weber ma. J Hypertens. 2006 Jul;24(7):1405-12. doi: 10.1097/01.hjh.0000234122.55895.5b. J Hypertens. 2006. PMID: 16794491 Clinical Trial.
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR. Julius S, et al. Among authors: weber ma. Hypertension. 2006 Sep;48(3):385-91. doi: 10.1161/01.HYP.0000236119.96301.f2. Epub 2006 Jul 24. Hypertension. 2006. PMID: 16864741 Clinical Trial.
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K. Weber MA, et al. Blood Press. 2007;16(1):13-9. doi: 10.1080/08037050701217643. Blood Press. 2007. PMID: 17453747 Clinical Trial.
1,144 results